amerihealth
Advanced Search
Type
  
Name
  
ID
  
MPDispTitle
  
Policy Category
  
MPPolicyNumber
  
MPPolicyNumberwithoutversion
  
MPPolicyPageName
  
MPTitle
  
Title
  
MPattachmentdataPub
f9cd203a-79ff-4e2b-a528-de895e67a9d1.aspx
  
1330Abatacept(Orencia®)forInjectionforIntravenousUseMA08.028jPharmacy (08)MA08.028jMA08.028f9cd203a-79ff-4e2b-a528-de895e67a9d1Abatacept (Orencia®) for Injection for Intravenous UseAbatacept (Orencia®) for Injection for Intravenous Use
{"1331": {"Id":1331,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":8939,"PolicyAttachmentPageName":"4a383499-d68a-41de-adf6-497f157070a6"},}
cc1a6539-080b-46db-b903-d4804467b8fa.aspx
  
1198AbortionMA11.010dSurgery (11)MA11.010dMA11.010cc1a6539-080b-46db-b903-d4804467b8faAbortionAbortion
ca5cf4f3-f26b-440a-9861-5d6da4e8efe2.aspx
  
1704AcupunctureMA12.004eMiscellaneous (12)MA12.004eMA12.004ca5cf4f3-f26b-440a-9861-5d6da4e8efe2AcupunctureAcupuncture
{"1705": {"Id":1705,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":9336,"PolicyAttachmentPageName":"9510ffe2-ac98-4597-b49c-fd1cd86428f2"},}
40a201d5-c72e-4858-8d07-5423c65af08d.aspx
  
969AcuteCareFacilityInpatientTransfersMA12.003bMiscellaneous (12)MA12.003bMA12.00340a201d5-c72e-4858-8d07-5423c65af08dAcute Care Facility Inpatient TransfersAcute Care Facility Inpatient Transfers
95b7c282-9261-42ad-8df3-2ab8f462523c.aspx
  
1255ADAMTS13,recombinant-krhn(Adzynma)MA08.171Pharmacy (08)MA08.171MA08.17195b7c282-9261-42ad-8df3-2ab8f462523cADAMTS13, recombinant-krhn (Adzynma)ADAMTS13, recombinant-krhn (Adzynma)
c16fa0c8-7e0b-41bf-b18d-34c34971191f.aspx
  
856Ado-TrastuzumabEmtansine(Kadcyla®)MA08.066gPharmacy (08)MA08.066gMA08.066c16fa0c8-7e0b-41bf-b18d-34c34971191fAdo-Trastuzumab Emtansine (Kadcyla®)Ado-Trastuzumab Emtansine (Kadcyla®)
{"857": {"Id":857,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":8440,"PolicyAttachmentPageName":"62ca80d5-8705-423a-8dd1-972f9aa029b6"},}
9bf1af05-ecaf-480f-a925-78a3aef533fd.aspx
  
1302Agalsidasebeta(Fabrazyme)andpegunigalsidasealfa-iwxj(Elfabrio)MA08.033dPharmacy (08)MA08.033dMA08.0339bf1af05-ecaf-480f-a925-78a3aef533fdAgalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio)Agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio)
66c3e611-3717-4969-b891-61d21233a143.aspx
  
1148AirAmbulanceServicesMA12.007bMiscellaneous (12)MA12.007bMA12.00766c3e611-3717-4969-b891-61d21233a143Air Ambulance ServicesAir Ambulance Services
cd081d46-88c8-49fc-9358-495cc20afd4a.aspx
  
977Alemtuzumab(Lemtrada®)MA08.015dPharmacy (08)MA08.015dMA08.015cd081d46-88c8-49fc-9358-495cc20afd4aAlemtuzumab (Lemtrada®)Alemtuzumab (Lemtrada®)
ae9a96dd-7fcc-42dd-8131-748117e301e2.aspx
  
993Alglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®),Cipaglucosidasealfa-atga(Pombiliti™)MA08.036gPharmacy (08)MA08.036gMA08.036ae9a96dd-7fcc-42dd-8131-748117e301e2Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ )Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ )
7c1d9cf9-dd9c-4e19-924e-ad01a9b72bda.aspx
  
1024AllergyImmunotherapyMA07.055dMedicine (07)MA07.055dMA07.0557c1d9cf9-dd9c-4e19-924e-ad01a9b72bdaAllergy ImmunotherapyAllergy Immunotherapy
93d63acf-a8cc-41bc-a2c5-18238795ccfb.aspx
  
1011Alpha1-AntitrypsinTherapy(e.g.,Prolastin-C,AralastNP,Glassia,Zemaira)MA08.050bPharmacy (08)MA08.050bMA08.05093d63acf-a8cc-41bc-a2c5-18238795ccfbAlpha 1-Antitrypsin Therapy (e.g., Prolastin-C, Aralast NP, Glassia, Zemaira)Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C, Aralast NP, Glassia, Zemaira)
3ddbe79c-6739-4e25-8e95-871ee34e6801.aspx
  
1708AlwaysBundledProcedureCodesMA00.026wAdministrative (00)MA00.026wMA00.0263ddbe79c-6739-4e25-8e95-871ee34e6801Always Bundled Procedure CodesAlways Bundled Procedure Codes
{"1709": {"Id":1709,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":9403,"PolicyAttachmentPageName":"5ef96895-5230-44ac-adf4-62f31184485b"},"1710": {"Id":1710,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (MPFSD Indicator B)","MPPolicyAttachmentInternalSourceId":9404,"PolicyAttachmentPageName":"f6de9ff6-d4ce-4691-aabc-aa8edd6b02d3"},"1711": {"Id":1711,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":9405,"PolicyAttachmentPageName":"6b882ed8-503d-42cd-aa82-b2986aab2f32"},}
0965b016-d0af-46b4-8b97-9e4f7af19146.aspx
  
829AmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)DevicesMA07.005cMedicine (07)MA07.005cMA07.0050965b016-d0af-46b4-8b97-9e4f7af19146Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) DevicesAmbulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices
d4dffffb-7db2-46a1-9bbf-5698edaed2d8.aspx
  
1661AmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)MonitoringMA07.026qMedicine (07)MA07.026qMA07.026d4dffffb-7db2-46a1-9bbf-5698edaed2d8Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) MonitoringAmbulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring
82bf3454-ff11-494a-82fc-4a277c9e2c6c.aspx
  
1081Amivantamab-vmjw(Rybrevant®)MA08.148aPharmacy (08)MA08.148aMA08.14882bf3454-ff11-494a-82fc-4a277c9e2c6cAmivantamab-vmjw (Rybrevant®)Amivantamab-vmjw (Rybrevant®)
5342b2c3-d175-483e-bbfd-63d920366304.aspx
  
1369AnesthesiaServicesforEpidural,ParavertebralFacetandSacroiliacJointInjectionsforSpinalJointManagementMA01.008cAnesthesia (01)MA01.008cMA01.0085342b2c3-d175-483e-bbfd-63d920366304Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint ManagementAnesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management
{}
ffb29139-c6b9-4389-9ceb-5670bc56e674.aspx
  
1137Anifrolumab-fnia(Saphnelo®)MA08.140cPharmacy (08)MA08.140cMA08.140ffb29139-c6b9-4389-9ceb-5670bc56e674Anifrolumab-fnia (Saphnelo®)Anifrolumab-fnia (Saphnelo®)
3279c85b-4f6c-4134-87cb-1c314c3f60c0.aspx
  
928Ankle-Foot/Knee-Ankle-FootOrthosesMA05.010jDME (05)MA05.010jMA05.0103279c85b-4f6c-4134-87cb-1c314c3f60c0Ankle-Foot/Knee-Ankle-Foot OrthosesAnkle-Foot/Knee-Ankle-Foot Orthoses
{"929": {"Id":929,"MPAttachmentLetter":"A","Title":"HCPCS CODES FOR ANKLE-FOOT/ KNEE-ANKLE FOOT ORTHOSIS","MPPolicyAttachmentInternalSourceId":8451,"PolicyAttachmentPageName":"9fca7e50-d4e4-4ead-a708-5f649d046039"},}
83351e2c-0a5c-49e3-bca7-f333d1078e85.aspx
  
165ApheresisTherapyMA06.001ePathology and Laboratory (06)MA06.001eMA06.00183351e2c-0a5c-49e3-bca7-f333d1078e85Apheresis TherapyApheresis Therapy
e3f4b785-821c-42a7-b608-7cfe7f542a0a.aspx
  
1542Apos®biomechanicalshoesystemMA05.070DME (05)MA05.070MA05.070e3f4b785-821c-42a7-b608-7cfe7f542a0aApos® biomechanical shoe systemApos® biomechanical shoe system
c3542857-3c91-4a43-90c5-1f396b6d349e.aspx
  
798ApplicationandRemovalofTattoosMA11.072Surgery (11)MA11.072MA11.072c3542857-3c91-4a43-90c5-1f396b6d349eApplication and Removal of TattoosApplication and Removal of Tattoos
e09477ca-37b6-4df8-949c-3203118199db.aspx
  
1089AqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucomaMA11.105jSurgery (11)MA11.105jMA11.105e09477ca-37b6-4df8-949c-3203118199dbAqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of GlaucomaAqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma
{"1090": {"Id":1090,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":8592,"PolicyAttachmentPageName":"c47da178-16d6-48ea-a433-139702744bf4"},}
46d052a1-42e0-4afc-b47d-746e3ba72aa7.aspx
  
1673AsparaginaseErwiniaChrysanthemi(recombinant)-rywn(Rylaze®)MA08.085iPharmacy (08)MA08.085iMA08.08546d052a1-42e0-4afc-b47d-746e3ba72aa7Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
5673ea03-86e3-4be3-a736-0a64f04760ac.aspx
  
1671Atezolizumab(Tecentriq®)andAtezolizumabwithHyaluronidase-tqjs(TecentriqHybrezaTM)MA08.127dPharmacy (08)MA08.127dMA08.1275673ea03-86e3-4be3-a736-0a64f04760acAtezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza TM)Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza TM)
{"1672": {"Id":1672,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9179,"PolicyAttachmentPageName":"2b3c9364-3beb-4628-9330-738c9a0568d4"},}
1196f21f-3450-490c-852b-febc54f66776.aspx
  
1078AuricularProsthesesMA05.068DME (05)MA05.068MA05.0681196f21f-3450-490c-852b-febc54f66776Auricular ProsthesesAuricular Prostheses
7bca59ad-97e6-4ed3-b236-0734deceedf7.aspx
  
1538AutomaticExternalCardioverterDefibrillators(WearableandNonwearable)MA05.005gDME (05)MA05.005gMA05.0057bca59ad-97e6-4ed3-b236-0734deceedf7Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)
{"1539": {"Id":1539,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":9243,"PolicyAttachmentPageName":"d72dfbd3-bbf6-4c8a-86b6-ee92332afa6d"},"1540": {"Id":1540,"MPAttachmentLetter":"A","Title":"ICD-10 codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":9244,"PolicyAttachmentPageName":"f77c87fe-25f6-4007-9f44-52fb84821a3d"},}
ccbfb000-08b5-4105-8b07-392f2718ff25.aspx
  
1382AutonomicNervousSystemTestingMA07.027gMedicine (07)MA07.027gMA07.027ccbfb000-08b5-4105-8b07-392f2718ff25Autonomic Nervous System TestingAutonomic Nervous System Testing
6a987f55-f913-4da6-88e6-62b7b311252c.aspx
  
1621Avelumab(Bavencio®)MA08.122dPharmacy (08)MA08.122dMA08.1226a987f55-f913-4da6-88e6-62b7b311252cAvelumab (Bavencio®)Avelumab (Bavencio®)
{"1622": {"Id":1622,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9268,"PolicyAttachmentPageName":"90877462-36a1-41c2-ab95-3654a49366d5"},}
73bad694-cd52-4998-8556-2034b60e2675.aspx
  
1496BalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitisorRecurrentAcuteRhinosinusitisMA11.100fSurgery (11)MA11.100fMA11.10073bad694-cd52-4998-8556-2034b60e2675Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis
ea8f920a-fc0b-497b-ad5e-a25e4944e36f.aspx
  
1069Belimumab(Benlysta®)forIntravenousUseMA08.057dPharmacy (08)MA08.057dMA08.057ea8f920a-fc0b-497b-ad5e-a25e4944e36fBelimumab (Benlysta®) for Intravenous UseBelimumab (Benlysta®) for Intravenous Use
e4ff28c3-83f1-406d-9641-86b5d2ff1b53.aspx
  
1603Bevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUseMA08.072oPharmacy (08)MA08.072oMA08.072e4ff28c3-83f1-406d-9641-86b5d2ff1b53Bevacizumab (Avastin®) and Related Biosimilars For Oncologic UseBevacizumab (Avastin®) and Related Biosimilars For Oncologic Use
{"1604": {"Id":1604,"MPAttachmentLetter":"A","Title":"ICD 10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":9219,"PolicyAttachmentPageName":"de59b461-e300-469f-8fcd-afe265d2bc65"},}
a943aaee-c928-4c2c-beee-17218edad0c2.aspx
  
35BillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampusMA00.037lAdministrative (00)MA00.037lMA00.037a943aaee-c928-4c2c-beee-17218edad0c2Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility CampusBilling for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus
{"36": {"Id":36,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus - CPT/HCPCS Codes","MPPolicyAttachmentInternalSourceId":7873,"PolicyAttachmentPageName":"a514181b-b263-4d9c-88cf-7d960f6de980"},}
9092ab12-85f9-4db7-af18-4a5b65ba07f0.aspx
  
1133BiofeedbackTherapyMA07.010cMedicine (07)MA07.010cMA07.0109092ab12-85f9-4db7-af18-4a5b65ba07f0Biofeedback TherapyBiofeedback Therapy
7afcb7bb-2baf-4668-9a41-2b522051ffec.aspx
  
1292BioimpedancefortheDetectionofLymphedemaMA07.052Medicine (07)MA07.052MA07.0527afcb7bb-2baf-4668-9a41-2b522051ffecBioimpedance for the Detection of LymphedemaBioimpedance for the Detection of Lymphedema
21145f4c-ee33-4aad-917a-30695c515a2d.aspx
  
1532Blinatumomab(Blincyto®)MA08.058gPharmacy (08)MA08.058gMA08.05821145f4c-ee33-4aad-917a-30695c515a2dBlinatumomab (Blincyto®) Blinatumomab (Blincyto®)
2098fab0-09bc-4325-aba2-2b77632a83b2.aspx
  
989Bone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAidsMA11.049gSurgery (11)MA11.049gMA11.0492098fab0-09bc-4325-aba2-2b77632a83b2Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing AidsBone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids
caa652b3-02e8-4521-bb10-d3acd06f60d9.aspx
  
1052BotulinumToxinAgentsMA08.017kPharmacy (08)MA08.017kMA08.017caa652b3-02e8-4521-bb10-d3acd06f60d9Botulinum Toxin AgentsBotulinum Toxin Agents
{"1053": {"Id":1053,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":8526,"PolicyAttachmentPageName":"93fad3c1-b2d8-4e73-9603-77cfe0195b84"},}
c104ca59-b0c0-4ba7-9b1c-853112eb5e7f.aspx
  
1549BrentuximabVedotin(Adcetris®)MA08.068kPharmacy (08)MA08.068kMA08.068c104ca59-b0c0-4ba7-9b1c-853112eb5e7fBrentuximab Vedotin (Adcetris®)Brentuximab Vedotin (Adcetris®)
{"1550": {"Id":1550,"MPAttachmentLetter":"A","Title":"ICD 10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":9002,"PolicyAttachmentPageName":"dc4f21e7-0c13-4061-afec-f7eb829ab68e"},}
62a855de-c1ea-4d37-9b01-a8d408546250.aspx
  
1067BronchialValvesMA11.020Surgery (11)MA11.020MA11.02062a855de-c1ea-4d37-9b01-a8d408546250Bronchial ValvesBronchial Valves
cd48927f-ea18-4d21-a20f-fc64084e9fb2.aspx
  
1025Burosumab-twza(Crysvita®)MA08.099bPharmacy (08)MA08.099bMA08.099cd48927f-ea18-4d21-a20f-fc64084e9fb2Burosumab-twza (Crysvita®)Burosumab-twza (Crysvita®)
24718575-f0ad-4bb7-a298-4cf311b11f9b.aspx
  
1608Canakinumab(Ilaris®)MA08.101cPharmacy (08)MA08.101cMA08.10124718575-f0ad-4bb7-a298-4cf311b11f9bCanakinumab (Ilaris®)Canakinumab (Ilaris®)
{"1609": {"Id":1609,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9271,"PolicyAttachmentPageName":"26c77500-4891-4873-9e46-706be27bdbd2"},}
90be0df6-4917-4222-a90b-99f6461b61f8.aspx
  
769CanesandCrutchesMA05.052bDME (05)MA05.052bMA05.05290be0df6-4917-4222-a90b-99f6461b61f8Canes and CrutchesCanes and Crutches
dabf0152-819f-40c4-8150-035de6fa9461.aspx
  
788CapsuleEndoscopyMA07.022eMedicine (07)MA07.022eMA07.022dabf0152-819f-40c4-8150-035de6fa9461Capsule EndoscopyCapsule Endoscopy
955aca1a-8275-47f3-9a8f-0f6d2682d8eb.aspx
  
851CardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)ProgramsMA10.002fRehabilitation Services (10)MA10.002fMA10.002955aca1a-8275-47f3-9a8f-0f6d2682d8ebCardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) ProgramsCardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs
{"852": {"Id":852,"MPAttachmentLetter":"A","Title":"Medically Necessary ICD-10 Codes","MPPolicyAttachmentInternalSourceId":8306,"PolicyAttachmentPageName":"4ede227c-bda6-49e3-b3b9-29b56415b1bf"},}
baf706da-50b3-4865-aaca-f619ddd95374.aspx
  
1707CareManagementandCarePlanningServicesMA00.006oAdministrative (00)MA00.006oMA00.006baf706da-50b3-4865-aaca-f619ddd95374Care Management and Care Planning ServicesCare Management and Care Planning Services
5a2dd532-c36f-483f-9348-8600916ede19.aspx
  
1548Carfilzomib(Kyprolis®)MA08.062jPharmacy (08)MA08.062jMA08.0625a2dd532-c36f-483f-9348-8600916ede19Carfilzomib (Kyprolis®)Carfilzomib (Kyprolis®)
baa5f89e-a39b-4277-bc0d-25cb3c212674.aspx
  
1321CastandSplintApplicationsandAssociatedSuppliesMA00.012cAdministrative (00)MA00.012cMA00.012baa5f89e-a39b-4277-bc0d-25cb3c212674Cast and Splint Applications and Associated SuppliesCast and Splint Applications and Associated Supplies
{"1322": {"Id":1322,"MPAttachmentLetter":"A","Title":"Procedures Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":8998,"PolicyAttachmentPageName":"f1396f83-4def-4eb7-b446-324bb3d5d1dd"},}
6d9edd1a-96ab-4fe5-b196-e98b567febd4.aspx
  
1138CataractSurgeryMA11.054eSurgery (11)MA11.054eMA11.0546d9edd1a-96ab-4fe5-b196-e98b567febd4Cataract SurgeryCataract Surgery
{"1139": {"Id":1139,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":8500,"PolicyAttachmentPageName":"2c59af64-e765-49f6-a784-b795ea526113"},}
f43f47dc-2ebc-4123-9180-843422b7186b.aspx
  
1652CatheterAblationofCardiacArrhythmiasMA11.060hSurgery (11)MA11.060hMA11.060f43f47dc-2ebc-4123-9180-843422b7186bCatheter Ablation of Cardiac ArrhythmiasCatheter Ablation of Cardiac Arrhythmias
96b211e5-6d32-4c5f-b8af-35d9af3bde2f.aspx
  
1553Cemiplimab-rwlc(Libtayo®)MA08.124dPharmacy (08)MA08.124dMA08.12496b211e5-6d32-4c5f-b8af-35d9af3bde2fCemiplimab-rwlc (Libtayo®)Cemiplimab-rwlc (Libtayo®)
8136c93c-9de8-4cec-be5d-15788042a569.aspx
  
1570Cerliponasealfa(Brineura®)MA08.089dPharmacy (08)MA08.089dMA08.0898136c93c-9de8-4cec-be5d-15788042a569Cerliponase alfa (Brineura®)Cerliponase alfa (Brineura®)
{"1571": {"Id":1571,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for Cerliponase alfa (Brineura®)","MPPolicyAttachmentInternalSourceId":9270,"PolicyAttachmentPageName":"e68f969d-b0be-41fc-812a-b94d6ef808bc"},}
8c9283e5-d136-42ad-9c04-beff05592e40.aspx
  
1611CervicalTractionDevicesforIn-homeUseMA05.009bDME (05)MA05.009bMA05.0098c9283e5-d136-42ad-9c04-beff05592e40Cervical Traction Devices for In-home UseCervical Traction Devices for In-home Use
a1c42244-6455-4cc1-8f06-d27da3998595.aspx
  
819Cetuximab(Erbitux®)MA08.031gPharmacy (08)MA08.031gMA08.031a1c42244-6455-4cc1-8f06-d27da3998595Cetuximab (Erbitux®)Cetuximab (Erbitux®)
{"820": {"Id":820,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":8348,"PolicyAttachmentPageName":"4bf0f992-d194-4a0c-b3e0-a79e4c2dee09"},"821": {"Id":821,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":8349,"PolicyAttachmentPageName":"1d86ffe4-e62b-444e-b83b-8e7083c04732"},}
867f33b5-7c1c-44d5-b3a7-7681208400e1.aspx
  
1427ChemicalPeelsMA11.103bSurgery (11)MA11.103bMA11.103867f33b5-7c1c-44d5-b3a7-7681208400e1Chemical PeelsChemical Peels
a424c297-ea16-4d99-a1fc-abafe3958e6d.aspx
  
1646ChimericAntigenReceptor(CAR)TherapyMA08.093oPharmacy (08)MA08.093oMA08.093a424c297-ea16-4d99-a1fc-abafe3958e6dChimeric Antigen Receptor (CAR) TherapyChimeric Antigen Receptor (CAR) Therapy
{"1647": {"Id":1647,"MPAttachmentLetter":"A","Title":"ICD 10 codes","MPPolicyAttachmentInternalSourceId":9355,"PolicyAttachmentPageName":"d85427bb-eb6c-49e7-9e19-bc1d9ae7ea57"},}
1bf4f989-e8fe-478c-92dc-271df20e0080.aspx
  
964ChiropracticServicesMA10.004iRehabilitation Services (10)MA10.004iMA10.0041bf4f989-e8fe-478c-92dc-271df20e0080Chiropractic ServicesChiropractic Services
ba5308b2-33de-4fef-b3be-67ac62a9b3c2.aspx
  
1610CoagulationFactorsMA08.004wPharmacy (08)MA08.004wMA08.004ba5308b2-33de-4fef-b3be-67ac62a9b3c2Coagulation FactorsCoagulation Factors
ad839354-6971-41a0-8d01-ad241d09fb08.aspx
  
1212Cobalamin(VitaminB12),FolicAcid,andHomocysteineTestingMA06.032aPathology and Laboratory (06)MA06.032aMA06.032ad839354-6971-41a0-8d01-ad241d09fb08Cobalamin (Vitamin B12), Folic Acid, and Homocysteine TestingCobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing
{"1213": {"Id":1213,"MPAttachmentLetter":"A","Title":"ICD 10 CODES FOR MEDICALLY NECESSARY COBALAMIN (VITAMIN B12), FOLIC ACID, AND/OR HOMOCYSTEINE TESTING (CPT CODES 82607, 82746, AND 83090)","MPPolicyAttachmentInternalSourceId":8881,"PolicyAttachmentPageName":"431da55a-4535-4af0-8bec-654d3a0b6a0b"},}
4a37023a-9005-494a-b45d-e871483492b0.aspx
  
918CochlearImplantationMA11.039eSurgery (11)MA11.039eMA11.0394a37023a-9005-494a-b45d-e871483492b0Cochlear ImplantationCochlear Implantation
fee78a0b-02d4-430c-b646-cfac446d41a4.aspx
  
800Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo®)MA08.128Pharmacy (08)MA08.128MA08.128fee78a0b-02d4-430c-b646-cfac446d41a4Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®)Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®)
37a80c47-f90c-47ee-b58c-d4b25d90306d.aspx
  
783CommodeChairsMA05.036bDME (05)MA05.036bMA05.03637a80c47-f90c-47ee-b58c-d4b25d90306dCommode ChairsCommode Chairs
2b9ece34-5173-46a4-821e-fa55c65cd42a.aspx
  
1065ComplementaryandIntegrativeHealthServicesMA12.001eMiscellaneous (12)MA12.001eMA12.0012b9ece34-5173-46a4-821e-fa55c65cd42aComplementary and Integrative Health ServicesComplementary and Integrative Health Services
432753c6-2f7e-4a74-9757-7fee1ebd8168.aspx
  
1245CompleteDecongestiveTherapy(CDT)MA07.042Medicine (07)MA07.042MA07.042432753c6-2f7e-4a74-9757-7fee1ebd8168Complete Decongestive Therapy (CDT)Complete Decongestive Therapy (CDT)
6c2c276e-9fa3-429e-bc58-9a5ee9545eba.aspx
  
920CompositeTissueAllotransplantationoftheHand(s)andFaceMA11.112Surgery (11)MA11.112MA11.1126c2c276e-9fa3-429e-bc58-9a5ee9545ebaComposite Tissue Allotransplantation of the Hand(s) and FaceComposite Tissue Allotransplantation of the Hand(s) and Face
16c95899-4a2d-4018-ae58-6808e5ab1663.aspx
  
1119CompressionGarmentsMA05.045eDME (05)MA05.045eMA05.04516c95899-4a2d-4018-ae58-6808e5ab1663Compression GarmentsCompression Garments
a3add4cc-055a-4e9d-9dfc-2b2c583f3862.aspx
  
1300Computer-AidedDetection(CAD)SystemforUsewithChestRadiographsMA09.014bRadiology (09)MA09.014bMA09.014a3add4cc-055a-4e9d-9dfc-2b2c583f3862Computer-Aided Detection (CAD) System for Use with Chest RadiographsComputer-Aided Detection (CAD) System for Use with Chest Radiographs
f59aa164-15c2-44b7-bbf6-da50748c61cc.aspx
  
828Computer-AssistedMusculoskeletalSurgicalNavigationalOrthopedicProcedureMA11.088cSurgery (11)MA11.088cMA11.088f59aa164-15c2-44b7-bbf6-da50748c61ccComputer-Assisted Musculoskeletal Surgical Navigational Orthopedic ProcedureComputer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure
81badbcb-c683-4b9d-a96f-79d468315497.aspx
  
1072ConsultationServicesMA00.049bAdministrative (00)MA00.049bMA00.04981badbcb-c683-4b9d-a96f-79d468315497Consultation ServicesConsultation Services
4dea1ca1-1d9c-4591-bc3f-6f63bd34d8db.aspx
  
1634ContinuousGlucoseMonitorsandHomeBloodGlucoseMonitorsandSuppliesMA00.002qAdministrative (00)MA00.002qMA00.0024dea1ca1-1d9c-4591-bc3f-6f63bd34d8dbContinuous Glucose Monitors and Home Blood Glucose Monitors and SuppliesContinuous Glucose Monitors and Home Blood Glucose Monitors and Supplies
{"1635": {"Id":1635,"MPAttachmentLetter":"B","Title":"Implantable Continuous Glucose Monitors (I-CGM)","MPPolicyAttachmentInternalSourceId":9369,"PolicyAttachmentPageName":"bf432957-35b7-4151-a1b0-94f2b8787e4e"},"1636": {"Id":1636,"MPAttachmentLetter":"A","Title":"ICD10: Long-Term Interstitial CGMS (Non-Implantable)","MPPolicyAttachmentInternalSourceId":9370,"PolicyAttachmentPageName":"9ccad97f-5010-44b5-a1e1-395df8bf63e1"},}
3f09acf7-614c-4f2a-8b31-3aeb51979ec9.aspx
  
43ContrastAgentsUsedinConjunctionwithEchocardiographyMA09.004cRadiology (09)MA09.004cMA09.0043f09acf7-614c-4f2a-8b31-3aeb51979ec9Contrast Agents Used in Conjunction with EchocardiographyContrast Agents Used in Conjunction with Echocardiography
34c18a0b-a842-405a-8e20-c6cadd85ed9e.aspx
  
1163CornealPachymetryUsingUltrasoundMA07.046gMedicine (07)MA07.046gMA07.04634c18a0b-a842-405a-8e20-c6cadd85ed9eCorneal Pachymetry Using UltrasoundCorneal Pachymetry Using Ultrasound
{"1164": {"Id":1164,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes Eligible to be Reported for Corneal Pachymetry Using Ultrasound","MPPolicyAttachmentInternalSourceId":8840,"PolicyAttachmentPageName":"93a2eb6e-392e-4fb6-ac7c-b826ebf7060b"},}
2c6f102c-dd07-432d-8393-709313f4074f.aspx
  
802CosmeticProceduresMA12.009aMiscellaneous (12)MA12.009aMA12.0092c6f102c-dd07-432d-8393-709313f4074fCosmetic ProceduresCosmetic Procedures
6c112be2-1a7e-41f5-904b-82a4223bec8b.aspx
  
1506CoverageofMedicalDevicesMA05.040bDME (05)MA05.040bMA05.0406c112be2-1a7e-41f5-904b-82a4223bec8bCoverage of Medical DevicesCoverage of Medical Devices
e50b9ce8-e5d2-4d1b-8d9d-90ad574baf5d.aspx
  
1130CranialElectrotherapyStimulationMA05.066dDME (05)MA05.066dMA05.066e50b9ce8-e5d2-4d1b-8d9d-90ad574baf5dCranial Electrotherapy StimulationCranial Electrotherapy Stimulation
cc15a385-6a4a-4ac8-9be9-35719baa321b.aspx
  
1555CriteriaforReimbursementofEmergencyRoomServicesMA00.044dAdministrative (00)MA00.044dMA00.044cc15a385-6a4a-4ac8-9be9-35719baa321bCriteria for Reimbursement of Emergency Room ServicesCriteria for Reimbursement of Emergency Room Services
ab27d4c8-099c-4c4c-80d4-c47744de1a1f.aspx
  
1095crizanlizumab-tmca(Adakveo®) MA08.109bPharmacy (08)MA08.109bMA08.109ab27d4c8-099c-4c4c-80d4-c47744de1a1fcrizanlizumab-tmca (Adakveo®) crizanlizumab-tmca (Adakveo®)
7537366c-2749-4ef1-9800-d753b3903800.aspx
  
1602Crovalimab-akkz(PiaSky)MA08.178Pharmacy (08)MA08.178MA08.1787537366c-2749-4ef1-9800-d753b3903800Crovalimab-akkz (PiaSky) Crovalimab-akkz (PiaSky)
770940e9-38a5-45bf-b7fb-0210a5cbab36.aspx
  
1237CryosurgicalAblationoftheProstateGlandMA11.022aSurgery (11)MA11.022aMA11.022770940e9-38a5-45bf-b7fb-0210a5cbab36Cryosurgical Ablation of the Prostate GlandCryosurgical Ablation of the Prostate Gland
c59bbcae-3c42-4cb4-9f47-846763ab2714.aspx
  
1276Daratumumab(Darzalex®),DaratumumabandHyaluronidase-fihj(DarzalexFaspro®)MA08.079lPharmacy (08)MA08.079lMA08.079c59bbcae-3c42-4cb4-9f47-846763ab2714Daratumumab (Darzalex®), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®)Daratumumab (Darzalex®), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®)
b77328f5-879d-4c4f-9440-7bf227a4df4e.aspx
  
1478DayRehabilitationMA10.005bRehabilitation Services (10)MA10.005bMA10.005b77328f5-879d-4c4f-9440-7bf227a4df4eDay RehabilitationDay Rehabilitation
25099058-e04b-498b-8894-0c8703c311ac.aspx
  
1017DebridementofMycoticandSymptomaticNon-MycoticHypertrophicToeNailsMA11.014gSurgery (11)MA11.014gMA11.01425099058-e04b-498b-8894-0c8703c311acDebridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe NailsDebridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails
{"1018": {"Id":1018,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":8635,"PolicyAttachmentPageName":"1656fe9e-ad44-4804-a38a-6c0444891118"},"1019": {"Id":1019,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":8636,"PolicyAttachmentPageName":"11bb7228-845a-4176-9455-1dd5fc1b782c"},"1020": {"Id":1020,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":8639,"PolicyAttachmentPageName":"65dbcfc4-9105-4242-8674-884de088cef1"},"1021": {"Id":1021,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":8641,"PolicyAttachmentPageName":"f2e03f20-1120-41a2-b54e-83ea9e582a3f"},"1022": {"Id":1022,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":8644,"PolicyAttachmentPageName":"de9304a6-7103-4a83-9b32-5be6c2db4733"},}
9d327dba-7bcb-4d59-8996-78341f24833f.aspx
  
1030DeepBrainStimulation(DBS)MA11.005hSurgery (11)MA11.005hMA11.0059d327dba-7bcb-4d59-8996-78341f24833fDeep Brain Stimulation (DBS)Deep Brain Stimulation (DBS)
a438eb90-4c60-48ff-8f69-c9d64b3382ab.aspx
  
1396Denosumab(Prolia®,Xgeva®),Romosozumab-aqqg(Evenity®)MA08.052mPharmacy (08)MA08.052mMA08.052a438eb90-4c60-48ff-8f69-c9d64b3382abDenosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)
{"1397": {"Id":1397,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes","MPPolicyAttachmentInternalSourceId":9057,"PolicyAttachmentPageName":"e8aa76fc-1dcd-4cc5-8b84-2d33304c5098"},}
6d686768-2451-450f-b5ff-39c3d07a51bd.aspx
  
1374DermabrasionforRhinophyma,Septoplasty,Rhinoplasty,andSeptorhinoplastyMA11.099eSurgery (11)MA11.099eMA11.0996d686768-2451-450f-b5ff-39c3d07a51bdDermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and SeptorhinoplastyDermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty
74bdf09b-06a0-450c-9fc7-1faf0d609876.aspx
  
471DirectAccesstoObstetrics/Gynecology(OB/GYN)ServicesMA00.032fAdministrative (00)MA00.032fMA00.03274bdf09b-06a0-450c-9fc7-1faf0d609876Direct Access to Obstetrics/Gynecology (OB/GYN) ServicesDirect Access to Obstetrics/Gynecology (OB/GYN) Services
bd96e219-dbb7-4a2d-8759-1897b4ce0ab6.aspx
  
1597DirectEndoscopicNecrosectomy(DEN)fortheTreatmentofPancreaticNecrosisMA11.115Surgery (11)MA11.115MA11.115bd96e219-dbb7-4a2d-8759-1897b4ce0ab6Direct Endoscopic Necrosectomy (DEN) for the Treatment of Pancreatic NecrosisDirect Endoscopic Necrosectomy (DEN) for the Treatment of Pancreatic Necrosis
751d409f-6fce-4dab-82fb-40fc562dcc1a.aspx
  
847Dofetilide(Tikosyn®)UseintheInpatientSettingMA08.021cPharmacy (08)MA08.021cMA08.021751d409f-6fce-4dab-82fb-40fc562dcc1aDofetilide (Tikosyn®) Use in the Inpatient SettingDofetilide (Tikosyn®) Use in the Inpatient Setting
82beb3a6-44d4-4115-ad2a-e541d322be71.aspx
  
858Dostarlimab-gxly(Jemperli)MA08.136ePharmacy (08)MA08.136eMA08.13682beb3a6-44d4-4115-ad2a-e541d322be71Dostarlimab-gxly (Jemperli)Dostarlimab-gxly (Jemperli)
6313f185-3f19-4b75-9ec3-10abc52ba10a.aspx
  
1501Drug-ElutingBeadsandBlandEmbolizationfortheTreatmentofHepaticMalignanciesMA07.041cMedicine (07)MA07.041cMA07.0416313f185-3f19-4b75-9ec3-10abc52ba10aDrug-Eluting Beads and Bland Embolization for the Treatment of Hepatic MalignanciesDrug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies
8c6e11cf-96e5-477c-ac28-403034852274.aspx
  
1451DurableMedicalEquipment(DME)MA05.044rDME (05)MA05.044rMA05.0448c6e11cf-96e5-477c-ac28-403034852274Durable Medical Equipment (DME)Durable Medical Equipment (DME)
{"1452": {"Id":1452,"MPAttachmentLetter":"B","Title":"Items that Do Not Meet the Definition of Durable Medical Equipment (DME) or Excluded from Coverage by Medicare","MPPolicyAttachmentInternalSourceId":9181,"PolicyAttachmentPageName":"aa814621-43aa-40ee-9a23-640d161db3a1"},"1453": {"Id":1453,"MPAttachmentLetter":"A2","Title":"Equipment that Meets the Definition of Durable Medical Equipment (DME)","MPPolicyAttachmentInternalSourceId":9182,"PolicyAttachmentPageName":"a24f78ca-61c0-45ab-b2c3-e16e5d113e0c"},"1454": {"Id":1454,"MPAttachmentLetter":"A1","Title":"Equipment that Meets the Definition of Durable Medical Equipment (DME)","MPPolicyAttachmentInternalSourceId":9183,"PolicyAttachmentPageName":"442b9bc9-daac-4b5a-99c0-53417f0d4bca"},}
7961a20b-70b6-4d08-a362-6da61ef8bc97.aspx
  
1507DurableMedicalEquipment(DME)NotSubjecttoaRentaltoPurchaseMaximumMA05.028eDME (05)MA05.028eMA05.0287961a20b-70b6-4d08-a362-6da61ef8bc97Durable Medical Equipment (DME) Not Subject to a Rental to Purchase MaximumDurable Medical Equipment (DME) Not Subject to a Rental to Purchase Maximum
e60e2d1d-5090-4238-8d74-da8a5ec7603f.aspx
  
1058Durvalumab(Imfinzi®)andTremelimumab-actl(Imjudo®)MA08.123dPharmacy (08)MA08.123dMA08.123e60e2d1d-5090-4238-8d74-da8a5ec7603fDurvalumab (Imfinzi®) and Tremelimumab-actl (Imjudo®)Durvalumab (Imfinzi®) and Tremelimumab-actl (Imjudo®)
{"1059": {"Id":1059,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":8515,"PolicyAttachmentPageName":"5c48cad9-d592-4d35-b216-c5392eebd130"},}
bab97c43-a2f5-461e-b1d8-09895c62c3a5.aspx
  
1651Eculizumab(Soliris®)andRelatedBiosimilars,Ravulizumab-cwvz(Ultomiris™)forintravenousadministrationMA08.044jPharmacy (08)MA08.044jMA08.044bab97c43-a2f5-461e-b1d8-09895c62c3a5Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™) for intravenous  administrationEculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™) for intravenous administration
2ae1a68f-6b24-4058-a7e5-752694e1bad9.aspx
  
1194Efbemalenograstimalfa-vuxw(Ryzneuta®),Eflapegrastim-xnst(Rolvedon™),Pegfilgrastim(Neulasta®)andRelatedBiosimilarsMA08.082mPharmacy (08)MA08.082mMA08.0822ae1a68f-6b24-4058-a7e5-752694e1bad9Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related BiosimilarsEfbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
{"1195": {"Id":1195,"MPAttachmentLetter":"A","Title":"EXAMPLES OF DISEASE SETTINGS AND CHEMOTHERAPY REGIMENS WITH A HIGH (>20%) OR INTERMEDIATE (10-20%) RISK FOR FEBRILE NEUTROPENIA","MPPolicyAttachmentInternalSourceId":8752,"PolicyAttachmentPageName":"4bdddc59-fc86-407e-be6c-910d24083c4e"},}
7989c8e0-524a-45f4-8de4-0a624fa1dd92.aspx
  
1439Efgartigimodalfa-fcab(Vyvgart)andefgartigimodalfaandhyaluronidase-qvfc(VyvgartHytrulo)MA08.142dPharmacy (08)MA08.142dMA08.1427989c8e0-524a-45f4-8de4-0a624fa1dd92Efgartigimod alfa - fcab (Vyvgart) and efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)Efgartigimod alfa - fcab (Vyvgart) and efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)
a55b92be-6ad0-472a-8d6a-13d0781e56e9.aspx
  
796ElectricalStimulationandElectromagneticStimulationfortheTreatmentofWoundsMA07.013dMedicine (07)MA07.013dMA07.013a55b92be-6ad0-472a-8d6a-13d0781e56e9Electrical Stimulation and Electromagnetic Stimulation for the Treatment of WoundsElectrical Stimulation and Electromagnetic Stimulation for the Treatment of Wounds
{"797": {"Id":797,"MPAttachmentLetter":"A","Title":"ICD-10 Coding","MPPolicyAttachmentInternalSourceId":8448,"PolicyAttachmentPageName":"bc9d5cd2-215e-49a4-a8fd-39aea25bfe5b"},}
f73a7df3-34fc-47eb-8984-ac387c1eddad.aspx
  
1023ElectroconvulsiveTherapy(ECT)MA14.001aBehavioral Health (14)MA14.001aMA14.001f73a7df3-34fc-47eb-8984-ac387c1eddadElectroconvulsive Therapy (ECT)Electroconvulsive Therapy (ECT)
5b2eb4f4-dae8-4896-8a84-fbbd7970c94c.aspx
  
865Electromyography(EMG)Studies,NerveConductionStudies(NCS),andRelatedElectrodiagnosticStudiesMA07.050lMedicine (07)MA07.050lMA07.0505b2eb4f4-dae8-4896-8a84-fbbd7970c94cElectromyography (EMG) Studies, Nerve Conduction Studies (NCS), and Related Electrodiagnostic StudiesElectromyography (EMG) Studies, Nerve Conduction Studies (NCS), and Related Electrodiagnostic Studies
{"866": {"Id":866,"MPAttachmentLetter":"A","Title":"Recommended Guidelines for Electrodiagnostic Studies","MPPolicyAttachmentInternalSourceId":8120,"PolicyAttachmentPageName":"38375e9f-5b33-4cc7-a30e-fa5853aed7fb"},"867": {"Id":867,"MPAttachmentLetter":"D","Title":"ICD-10 Codes - Needle Electromyography for Guidance in Conjunction with Chemodenervation","MPPolicyAttachmentInternalSourceId":8436,"PolicyAttachmentPageName":"551e073c-1c77-42d7-93f9-b88c29738efc"},"868": {"Id":868,"MPAttachmentLetter":"B","Title":"ICD10 Codes - Needle Electromyography and Nerve Conduction Studies","MPPolicyAttachmentInternalSourceId":8441,"PolicyAttachmentPageName":"23be52a8-9a0e-4d4a-861b-f9d1aa616df1"},"869": {"Id":869,"MPAttachmentLetter":"C","Title":"ICD10 Codes - Electromyography of Anal or Urethral Sphincter","MPPolicyAttachmentInternalSourceId":8498,"PolicyAttachmentPageName":"8f609a7a-c5a2-4912-b97a-58215fff334e"},"870": {"Id":870,"MPAttachmentLetter":"E","Title":"ICD10 Codes - Neuromuscular Junction Testing","MPPolicyAttachmentInternalSourceId":8499,"PolicyAttachmentPageName":"965d952f-a21a-4976-9f65-1ac04edb8f9d"},"871": {"Id":871,"MPAttachmentLetter":"F","Title":"ICD10 Codes - Somatosensory Evoked Potentials (SSEPs)","MPPolicyAttachmentInternalSourceId":8502,"PolicyAttachmentPageName":"b5527a94-6a17-4515-888a-c6a7ce1f7273"},}
01b304c6-6552-45f6-bac9-4c42a623f121.aspx
  
994Elranatamab-bcmm(Elrexfio™)MA08.168Pharmacy (08)MA08.168MA08.16801b304c6-6552-45f6-bac9-4c42a623f121Elranatamab-bcmm (Elrexfio™)Elranatamab-bcmm (Elrexfio™)
1 - 100Next